search
Back to results

Preoperative Immunonutrition in Patients Undergoing Elective Colorectal Surgery for Neoplasm

Primary Purpose

Cancer of Colon, Nutrition Related Cancer

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Placebo
Oral Impact Nestle
Colorectal surgery
Sponsored by
University of Roma La Sapienza
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cancer of Colon

Eligibility Criteria

20 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: primary colorectal neoplasms eligible for elective surgery, undergoing minivasive resections. 20 to 85 years old, with no difficulties in oral intake BMI ranging from 18 to 40. Exclusion Criteria: emergency surgery, converted procedures, major intraoperative complications, concomitant chronic disease such as chronic renal failure, rheumatic and hematological disease, chronic inflammatory bowel diseases, synchronous cancer, previous bowel resections or bariatric surgery, presence of preoperative stoma.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    A, Impact oral + Colorectal Surgery

    B, Placebo group + Colorectal Surgery

    Arm Description

    the supplement Oral Impact will be administered 3 times a day for 10 days before the operation. Colon surgery will be performed according to standard clinical practice.

    A Placebo will be administered 3 times a day for 10 days before the operation. Colon surgery will be performed according to standard clinical practice.

    Outcomes

    Primary Outcome Measures

    Surgical site infection (SSI)
    Number of participants developing surgical site infections (SSI), defined as wound/parietal infection or intra-abdominal abscess without any anastomotic leak.

    Secondary Outcome Measures

    Anastomotic leakage (AL)
    Number of participants developing anastomotic leakage (AL), defined as the evidence of leakage at the ileocolic or colo-colic or colo-rectal anastomosis, diagnosed with imaging modalities or with reoperation
    Length of stay (LOS)
    Mean and Median Length of stay (LOS), defined as the mean and median number of days of hospitalization from the day of the surgical procedure to the day of patients' discharge
    Inflammatory infiltration in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
    Number of inflammatory cells in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.).
    grade of fibrosis in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
    Number of fibroblasts in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.).
    Adipocytes cross sectional area (CSA) in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
    Adipocytes cross sectional area (CSA) in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.).

    Full Information

    First Posted
    March 15, 2023
    Last Updated
    June 22, 2023
    Sponsor
    University of Roma La Sapienza
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05916001
    Brief Title
    Preoperative Immunonutrition in Patients Undergoing Elective Colorectal Surgery for Neoplasm
    Official Title
    Multicenter RCT on Effects of Preoperative Immunonutrition on Patients Undergoing Elective Colorectal Surgery for Neoplasm: Changes in Adipose Tissue Inflammation and Correlation With Surgical Outcome for Future ERAS Guidelines.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 1, 2023 (Anticipated)
    Primary Completion Date
    March 31, 2025 (Anticipated)
    Study Completion Date
    October 31, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Roma La Sapienza

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Enhanced Recovery After Surgery (ERAS) protocols were developed to standardize perioperative practice in colon surgery to reduce morbidity, improve recovery, and shorten length of stay (LOS). Better protocol adherence translates into fewer readmissions and complications, and better 5-year survival. Preoperative elements, especially nutrition and immunonutrition, are topics that need further development to become the standard of care. It has been widely reported that the prevalence of malnutrition reaches 40% in cancer patients at the time of diagnosis. Impaired nutritional status at the time of surgery and cancer-induced inflammation, along with postoperative inflammatory responses to major surgery, increase the risk of postoperative complications, along with a decrease in perceived quality of life. Immunonutrition can modulate inflammation and reduce postoperative infections and shorten length of stay by counteracting the immune response induced by cancer. Adipose tissue has been shown to be a relevant source of inflammatory mediators, which may play a role in the promotion of tumor cachexia. The present study is a multicenter randomized control study (RCT) designed to evaluate the effect of preoperative immunonutrition in patients with colorectal cancer eligible for elective minimally invasive procedures, evaluating in particular surgical site infection and length of hospital stay. A biopsy of subcutaneous adipose tissue and visceral adipose tissue will also be performed, in order to evaluate the differences between inflammatory infiltrate, degree of fibrosis and cross-sectional area of adipocytes compared to controls.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cancer of Colon, Nutrition Related Cancer

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    216 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    A, Impact oral + Colorectal Surgery
    Arm Type
    Active Comparator
    Arm Description
    the supplement Oral Impact will be administered 3 times a day for 10 days before the operation. Colon surgery will be performed according to standard clinical practice.
    Arm Title
    B, Placebo group + Colorectal Surgery
    Arm Type
    Placebo Comparator
    Arm Description
    A Placebo will be administered 3 times a day for 10 days before the operation. Colon surgery will be performed according to standard clinical practice.
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Oral Impact Nestle
    Intervention Description
    Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
    Intervention Type
    Procedure
    Intervention Name(s)
    Colorectal surgery
    Intervention Description
    Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
    Primary Outcome Measure Information:
    Title
    Surgical site infection (SSI)
    Description
    Number of participants developing surgical site infections (SSI), defined as wound/parietal infection or intra-abdominal abscess without any anastomotic leak.
    Time Frame
    30 days after the surgical procedure
    Secondary Outcome Measure Information:
    Title
    Anastomotic leakage (AL)
    Description
    Number of participants developing anastomotic leakage (AL), defined as the evidence of leakage at the ileocolic or colo-colic or colo-rectal anastomosis, diagnosed with imaging modalities or with reoperation
    Time Frame
    30 days after the surgical procedure
    Title
    Length of stay (LOS)
    Description
    Mean and Median Length of stay (LOS), defined as the mean and median number of days of hospitalization from the day of the surgical procedure to the day of patients' discharge
    Time Frame
    at patients' discharge
    Title
    Inflammatory infiltration in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
    Description
    Number of inflammatory cells in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.).
    Time Frame
    at the time of tissue analysis, usually 1 month after surgery
    Title
    grade of fibrosis in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
    Description
    Number of fibroblasts in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.).
    Time Frame
    at the time of tissue analysis, usually 1 month after surgery
    Title
    Adipocytes cross sectional area (CSA) in the subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT)
    Description
    Adipocytes cross sectional area (CSA) in the specimens of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as stated in a previous study published by the investigators (Molfino A, J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342.).
    Time Frame
    at the time of tissue analysis, usually 1 month after surgery

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: primary colorectal neoplasms eligible for elective surgery, undergoing minivasive resections. 20 to 85 years old, with no difficulties in oral intake BMI ranging from 18 to 40. Exclusion Criteria: emergency surgery, converted procedures, major intraoperative complications, concomitant chronic disease such as chronic renal failure, rheumatic and hematological disease, chronic inflammatory bowel diseases, synchronous cancer, previous bowel resections or bariatric surgery, presence of preoperative stoma.

    12. IPD Sharing Statement

    Learn more about this trial

    Preoperative Immunonutrition in Patients Undergoing Elective Colorectal Surgery for Neoplasm

    We'll reach out to this number within 24 hrs